Rachel C. Gomez

Rachel C. Gomez

Auto-generated profile, based on publicly available information

Rachel C. Gomez

Department of Research and Development, Nature's Toolbox Inc, Rio Rancho, NM, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
EPElena Purlyte
Elena Purlyte
HDHerschel S Dhekne
Herschel S Dhekne
Adil R. SarhanAdil R. Sarhan
Adil R. Sarhan
RGRachel Gomez
Rachel Gomez
PLPaweł Lis
Paweł Lis
DADario R Alessi
Dario R Alessi
Parkinson's disease predisposing LRRK2 kinase phosphorylates a group of Rab GTPase proteins including Rab29, within the effector‐binding switch II motif. Previous work indicated that Rab29, located within the PARK16 locus mutated in Parkinson's patients, operates in a common pathway with LRRK2. Here, we show that Rab29 recruits LRRK2 to the trans ‐Golgi network and greatly stimulates its kinase activity. Pathogenic LRRK2 R1441G/C and Y1699C mutants that promote GTP binding are more readily recruited to the Golgi and activated by Rab29 than wild‐type LRRK2. We identify conserved residues within the LRRK2 ankyrin domain that are required for Rab29‐mediated Golgi recruitment and kinase activation. Consistent with these findings, knockout of Rab29 in A549 cells reduces endogenous LRRK2‐mediated phosphorylation of Rab10. We show that mutations that prevent LRRK2 from interacting with either Rab29 or GTP strikingly inhibit phosphorylation of a cluster of highly studied biomarker phosphorylation sites (Ser910, Ser935, Ser955 and Ser973). Our data reveal that Rab29 is a master regulator of LRRK2, controlling its activation, localization, and potentially biomarker phosphorylation.

6 November 2018 in eLife
Verified
Journal Article
Open access
HDHerschel S Dhekne
Herschel S Dhekne
IYIzumi Yanatori
Izumi Yanatori
RGRachel C Gomez
Rachel C Gomez
FTFrancesca Tonelli
Francesca Tonelli
FDFederico Diez
Federico Diez
SPSuzanne R Pfeffer
Suzanne R Pfeffer
Parkinson’s disease-associated LRRK2 kinase phosphorylates multiple Rab GTPases, including Rab8A and Rab10. We show here that LRRK2 kinase interferes with primary cilia formation in cultured cells, human LRRK2 G2019S iPS cells and in the cortex of LRRK2 R1441C mice. Rab10 phosphorylation strengthens its intrinsic ability to block ciliogenesis by enhancing binding to RILPL1. Importantly, the ability of LRRK2 to interfere with ciliogenesis requires both Rab10 and RILPL1 proteins. Pathogenic LRRK2 influences the ability of cells to respond to cilia-dependent, Hedgehog signaling as monitored by Gli1 transcriptional activation. Moreover, cholinergic neurons in the striatum of LRRK2 R1441C mice show decreased ciliation, which will decrease their ability to sense Sonic hedgehog in a neuro-protective circuit that supports dopaminergic neurons. These data reveal a molecular pathway for regulating cilia function that likely contributes to Parkinson’s disease-specific pathology.Editorial note: This article has been through an editorial process in which the authors decide how to respond to the issues raised during peer review. The Reviewing Editor's assessment is that all the issues have been addressed (see decision letter).

17 October 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
RGRachel C. Gomez
Rachel C. Gomez
PWPaulina Wawro
Paulina Wawro
PLPaweł Lis
Paweł Lis
DADario R. Alessi
Dario R. Alessi
SPSuzanne R. Pfeffer
Suzanne R. Pfeffer
LRRK2 kinase mutations cause familial Parkinson’s disease and increased phosphorylation of a subset of Rab GTPases. Rab29 recruits LRRK2 to the trans-Golgi and activates it there, yet some of LRRK2’s major Rab substrates are not on the Golgi. We sought to characterize the cell biology of LRRK2 activation. Unlike other Rab family members, we show that Rab29 binds nucleotide weakly, is poorly prenylated, and is not bound to GDI in the cytosol; nevertheless, Rab29 only activates LRRK2 when it is membrane bound and GTP bound. Mitochondrially anchored, GTP-bound Rab29 is both a LRRK2 substrate and activator, and it drives accumulation of active LRRK2 and phosphorylated Rab10 on mitochondria. Importantly, mitochondrially anchored LRRK2 is much less capable of phosphorylating plasma membrane–anchored Rab10 than soluble LRRK2. These data support a model in which LRRK2 associates with and dissociates from distinct membrane compartments to phosphorylate Rab substrates; if anchored, LRRK2 can modify misdelivered Rab substrates that then become trapped there because GDI cannot retrieve them.

15 June 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DCDanny Hung-Chieh Chou
Danny Hung-Chieh Chou
AVAmedeo Vetere
Amedeo Vetere
ACAmit Choudhary
Amit Choudhary
SSStephen S. Scully
Stephen S. Scully
MSMonica Schenone
Monica Schenone
BWBridget Wagner
Bridget Wagner

1 May 2026 in Molecular Therapy Advances
Verified
Journal Article
Open access
RKRyan Kilburn
Ryan Kilburn
RGRachel C. Gomez
Rachel C. Gomez
SESteven Evans
Steven Evans
Incorporation of the 5′ cap into RNA is a critical quality attribute that requires accurate assessment for therapeutic application. Existing analytical approaches often rely on transcript-specific probes or sequence-dependent workflows, which limit throughput and platform-level applicability. Here, we describe a quantitative, transcript-independent LC-MS/MS assay for RNA cap incorporation designed to support RNA therapeutic process development and quality control, using CleanCap-AG as a representative co-transcriptional capping chemistry. The workflow combines nuclease P1 digestion with external calibration using authentic cap analog standards, enabling quantification of capped (CC-A) and uncapped (ATP) 5′ species while correcting for residual unincorporated reagents through paired digested and undigested analyses. The assay supports a 0.01–20 pmol calibration range using commercially available standards and a 10 min LC-MS/MS acquisition, facilitating high analytical throughput. Analytical characterization demonstrated excellent linearity (r2 > 0.995), accuracy (84%–102% recovery), and precision consistent with accepted bioanalytical criteria (RSD <15% at 1 and 10 pmol). Application to multiple RNA transcripts confirmed efficient digestion and accurate cap quantification independent of sequence context. This method provides a rigorously characterized, sequence-agnostic analytical platform for RNA cap analysis compatible with chemical and potentially enzymatic capping strategies, enabling scalable process development, lot comparability assessment, and manufacturing quality control.